Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody
The disclosure provides compositions, kits, and methods of using a GDF-8 inhibitor to increase lean muscle mass. In embodiments, a GDF-8 inhibitor is an antibody or antigen binding fragment thereof that specifically binds GDF-8. In embodiments, a method comprises providing an exercise regimen for the subject, and administering a composition comprising an effective amount of a GDF-8 inhibitor.
1. A method for increasing lean body mass in a subject comprising:
a. providing an exercise regimen for the subject, wherein the exercise regimen comprises resistance training; and
b. administering a composition comprising an effective amount of a Growth and Differentiation Factor-8 (GDF-8) inhibitor to the subject, wherein the GDF-8 inhibitor is an antibody or antigen binding fragment thereof that specifically binds GDF-8, and comprises
three heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 360, and
three light chain complementarity determining regions (LCDR1, LCDR2, LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:368,
wherein the subject exhibits increased lean body mass compared to baseline value.
2. The method of claim 1 , wherein the effective amount is at least 400 mg.
3. The method of claim 1 , wherein the effective amount comprises a dosing regimen selected from a group consisting of at least 0.1 mg/kg to about 10 mg/kg, 1 mg/kg to about 10 mg/kg or 10 mg/kg to 100 mg/kg.
4. The method of claim 1 , wherein the effective amount comprises a dosing regimen selected from a group consisting of a single dose of about 0.01 to about 20 mg/kg body weight, about 0.1 to about 10 mg/kg body weight, or about 0.1 to about 5 mg/kg body weight.
5. The method of claim 1 , wherein the resistance training includes a set of exercises for training of a muscle selected from the group consisting of the dominant hand, non-dominant hand, leg, arm, chest and combinations thereof.
6. The method of claim 1 , wherein the composition is administered at least once every four weeks, once every two weeks, once a week, twice a week, three times a week, four times a week, or five times a week.
7. The method of claim 1 , wherein the composition is formulated for intravenous, subcutaneous, or oral administration.
8. The method of claim 7 , wherein the composition is formulated for subcutaneous administration.
9. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a HCVR amino acid sequence and a LCVR amino acid sequence, wherein the HCVR/LCVR sequence pair comprises the amino acid sequences of SEQ ID NO: 360/368.
10. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the HCDR3 amino acid sequence of SEQ ID NO: 366.
11. The method of claim 10 , wherein the antibody or antigen-binding fragment thereof comprises the LCDR3 amino acid sequence of SEQ ID NO: 371.
12. The method of claim 10 , wherein the antibody or antigen binding fragment thereof comprises the HCDR1 amino acid sequence of SEQ ID NO: 362.
13. The method of claim 12 , wherein the antibody or antigen binding fragment thereof comprises the HCDR2 amino acid sequence of SEQ ID NO: 364.
14. The method of claim 11 , wherein the antibody or antigen binding fragment thereof further comprises the LCDR1 amino acid sequence of SEQ ID NO: 370.
15. The method of claim 14 , wherein the antibody or fragment thereof further comprises the LCDR2 amino acid sequence of SEQ ID NO: 372.
16. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises HCDR1, HCDR2 and HCDR3 amino acid sequences of SEQ ID NOs: 362/364/366 and LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NOs: 370/372/374.
17. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises
three heavy chain CDRs (HCDR1, HCDR2, HCDR3) contained within the HCVR encoded by the nucleotide sequence of SEQ ID NO: 359, or a substantially similar sequence having at least 95% homology thereof, and
three light chain CDRs (LCDR1, LCDR2, LCDR3) contained within the LCVR encoded by the nucleotide sequence of SEQ ID NO: 367, or a substantially similar sequence having at least 95% homology thereof.
18. The method of claim 1 , wherein the subject is experiencing age related loss of lean muscle mass and/or post-surgical muscle wasting.
19. The method of claim 1 , wherein the subject is 60 years of age or older.
20. The method of claim 1 , wherein the subject is a human subject.
21. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof specifically binds mature GDF8 protein comprising the amino acid sequence of SEQ ID NO: 340.
22. The method of claim 1 , wherein the increase in lean body mass is determined by dual x-ray absorptiometry compared to baseline.
23. The method of claim 22 , wherein the increase in lean body mass is an increase in total lean body mass determined by dual x-ray absorptiometry compared to baseline.
24. A method of treating a disease in a subject comprising
administering a composition comprising an effective amount of a Growth and Differentiation Factor-8 (GDF-8) inhibitor to the subject, wherein the GDF-8 inhibitor is an antibody or antigen binding fragment thereof that specifically binds GDF-8, and comprises
three heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) contained within the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 360, and
three light chain complementarity determining regions (LCDR1, LCDR2, LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 368; and
providing an exercise regimen for the subject, wherein the exercise regimen comprises resistance training, wherein the disease is selected from a group consisting of sarcopenia, cachexia, muscle injury, muscle wasting, muscle atrophy and Sporadic Inclusion Body Myositis (sIBM), and wherein the subject exhibits increased lean body mass compared to baseline value.
25. The method of claim 24 , wherein the antibody or antigen binding fragment thereof comprises heavy and light chain variable domains (HCVR/LCVR) comprising amino acid sequences of SEQ ID NO: 360/368.
26. The method of claim 24 , wherein the antibody or antigen binding fragment thereof comprises HCDR1, HCDR2 and HCDR3 amino acid sequences of SEQ ID NO: 362/364/366, respectively; and LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NO: 370/372/374, respectively.
27. The method of claim 24 , wherein the antibody or antigen-binding fragment thereof specifically binds mature GDF8 protein comprising the amino acid sequence of SEQ ID NO: 340.
28. The method of claim 24 , wherein the increase in lean body mass is determined by dual x-ray absorptiometry compared to baseline.
29. The method of claim 28 , wherein the increase in lean body mass is an increase in total lean body mass determined by dual x-ray absorptiometry compared to baseline.